{"entity":{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","aka":[],"tldr":"Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas.","summary":"Eric Jonasch is a genitourinary medical oncologist at MD Anderson Cancer Center and directs its von Hippel-Lindau clinical centre. He was first author of the 2021 New England Journal of Medicine report of the phase 2 trial in which the HIF-2α inhibitor belzutifan shrank renal cell carcinomas and also pancreatic lesions and central nervous system haemangioblastomas in patients with VHL disease, leading to the first approval of a drug for the syndrome.","asOf":"2026-09-18","links":[],"tags":["kidney","targeted-therapy","trialist"],"related":[],"cancers":["spinal-cord-tumours","clear-cell-rcc","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-belzutifan-vhl-jonasch-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Genitourinary medical oncologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Kidney cancer","Von Hippel-Lindau disease","HIF-2α inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jonasch%5BAuthor%5D"}],"papers":[]},"route":"/people/eric-jonasch/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"paper":[{"id":"paper-belzutifan-vhl-jonasch-nejm-2021","kind":"paper","name":"Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease","route":"/key-papers/paper-belzutifan-vhl-jonasch-nejm-2021/"}]}}